Akeso's Ivonescimab Achieves Fourth Breakthrough Therapy Designation in China for First-Line Triple-Negative Breast Cancer, Marking Major Milestone in Asian Biopharma Innovation
Monday, November 03, 2025
On November 3, 2025, Akeso Inc. (HKEX: 9926.HK), a leading Chinese biopharmaceutical firm, announced that the company’s innovative bispecific antibody ivonescimab (PD-1/VEGF), in combination with chemotherapy, has been awarded a fourth Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for use as a first-line treatment of triple-negative breast cancer (TNBC). This regulatory recognition positions ivonescimab at the forefront of Asia’s evolving oncology pipeline and underscores the region’s growing strategic importance in global cancer R&D and regulatory advancement.
This designation comes as part of China’s increasing commitment to accelerate the development and approval of urgently needed therapies for high-burden diseases. The ongoing HARMONi-BC1/AK112-308, a Phase III multicenter, randomized, double-blind clinical trial, is designed to test ivonescimab’s efficacy and safety for TNBC—a cancer subtype with limited approved treatments and high unmet need in Asia and globally.
Ivonescimab’s multiple designations reflect a larger R&D and policy trend in China, where authorities are moving swiftly to recognize and facilitate medicines that demonstrate significant clinical advantage. The previous three BTDs for ivonescimab included combinations for non-small cell lung cancer (NSCLC), covering first-line PD-L1 positive NSCLC, use after EGFR-TKI resistance, and combinations with docetaxel post-PD-1/PD-L1 and platinum chemo failures. Notably, two of these indications have already been approved and entered China’s National Reimbursement Drug List. Ivonescimab’s progress provides case evidence for the effectiveness of China’s evolving regulatory flexibility in bringing novel therapies to market faster.
Akeso’s business model exemplifies the integration of end-to-end innovation within the Asian biopharma ecosystem. The company’s ACE Platform and Tetrabody bispecific antibody technology support a pipeline exceeding 50 innovative assets across oncology, autoimmune, metabolic, and inflammatory diseases. Twenty-four of these have entered clinical development. Akeso has established its own GMP-compliant manufacturing infrastructure and retained internal control over product commercialization, reflecting a trend towards vertically integrated R&D and manufacturing in the region. Furthermore, as these breakthroughs gain regulatory momentum at home, Akeso’s strategy involves rapid expansion of its pivotal Phase III programs on a global scale, with 14 late-stage studies now underway internationally (including four large multicenter trials).
Asia’s clinical trial environment—particularly in cancer—has become a locus for global partnership and technology exchange due to a combination of large patient populations, streamlined regulatory timelines, and rising government support for high-value biotherapeutic innovation. In the case of ivonescimab, regulatory validation across four major indications within three years demonstrates how Asian companies are closing the translational gap between preclinical discovery, clinical validation, and commercial scaling.
With nearly 20 Phase II clinical programs for ivonescimab targeting over ten additional indications (including cold tumors such as MSS/pMMR colorectal cancer and pancreatic cancer), Akeso’s pipeline is expected to continue expanding. This latest BTD for TNBC is likely to accelerate formal approval, bolster cross-border licensing and co-development interest, and power further R&D investment by both Akeso and the wider Asian biopharma sector. The growing volume of such regulatory milestones in the Asia-Pacific region is reshaping global business development strategies, leading to increased M&A, out-licensing, and regional manufacturing partnerships as multinationals and regional players alike vie for access to large, fast-growing patient pools in China and its neighbors.
In conclusion, Akeso’s fourth BTD for ivonescimab for first-line TNBC illustrates both the speed and scope of Asian-driven biopharma innovation. The company’s multi-modality development platform, local regulatory acumen, and commitment to large-scale, late-stage clinical programs underpin Asia’s ascent in the global life sciences hierarchy. For pharmaceutical executives and business strategists, the evolving BTD and accelerated approval landscape in China offers substantial opportunities—and growing competition—in high-value biotherapeutics and oncology portfolios.
